Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2024.2380469
Abstract: ABSTRACT Introduction To reduce the risk of disease recurrence and progression of intermediate and high-risk Non-Muscle Invasive Bladder Cancers (NMIBCs), intravesical adjuvant treatment with Bacillus Calmette-Guerin (BCG) represents the standard of care, although up to… read more here.
Keywords: bcg unresponsive; treatment; muscle invasive; invasive bladder ... See more keywords
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2024.2365802
Abstract: ABSTRACT Introduction BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) represent a significant therapeutic challenge in the treatment of bladder cancer. Nadofaragene firadenovec, represents a breakthrough in this area, offering a novel approach for the treatment of… read more here.
Keywords: bcg unresponsive; treatment; bladder cancer; nadofaragene firadenovec ... See more keywords
PD03-02 PHASE 3 RESULTS OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000823.02
Abstract: INTRODUCTION AND OBJECTIVE:Alternatives to radical cystectomy (RC) are critically needed for the treatment of high-risk BCG-unresponsive NMIBC. Vicinium is a recombinant fusion protein comprised of... read more here.
Keywords: phase results; bcg unresponsive; results vicinium; vicinium bcg ... See more keywords
PD12-01 ONCOFID-P-B FOR THE TREATMENT OF BCG UNRESPONSIVE CARCINOMA IN SITU (CIS) OF BLADDER
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000846.01
Abstract: INTRODUCTION AND OBJECTIVE:There is an unmet clinical need for new drugs able to delay or avoid cystectomy in patients with CIS unresponsive to BCG. Oncofid - P-B, a new drug that originates from t... read more here.
Keywords: pd12 oncofid; bcg unresponsive; unresponsive carcinoma; treatment bcg ... See more keywords
Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000001515
Abstract: PURPOSE Patients with BCG-unresponsive carcinoma in situ (CIS) are treated with radical cystectomy (RCx) or salvage intravesical chemotherapy (SIC). Recently, pembrolizumab was approved for BCG-unresponsive CIS. MATERIALS AND METHODS We used a decision-analytic Markov model… read more here.
Keywords: bcg unresponsive; pembrolizumab; cost effective; rcx ... See more keywords
Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Current Opinion in Urology"
DOI: 10.1097/mou.0000000000000846
Abstract: PURPOSE OF REVIEW A number of promising therapies for Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer (NMIBC) are in the pipeline. In this review, we discuss the history of immunotherapy for the treatment of… read more here.
Keywords: bcg unresponsive; cancer; calmette guerin; guerin bcg ... See more keywords
Contemporary outcomes of bladder carcinoma in situ treated with an adequate BCG immunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "BJU international"
DOI: 10.1111/bju.15567
Abstract: OBJECTIVE To assess whether bacillus Calmette-Guérin (BCG) responsiveness after initiation of an adequate BCG treatment (at least five of six instillations of induction and at least two of three instillations of maintenance) impacts oncological outcomes… read more here.
Keywords: bcg immunotherapy; adequate bcg; bcg unresponsive; months iqr ... See more keywords
Cost‐effectiveness analysis of different treatment modalities in BCG‐unresponsive NMIBC
Sign Up to like & getrecommendations! Published in 2024 at "BJU International"
DOI: 10.1111/bju.16332
Abstract: Radical cystectomy (RC) is the standard of care (SOC) in BCG‐unresponsive NMIBC and is associated with a significant health‐related quality‐of‐life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC)… read more here.
Keywords: bcg unresponsive; unresponsive nmibc; effectiveness analysis; treatment modalities ... See more keywords
Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
Sign Up to like & getrecommendations! Published in 2022 at "BMC Urology"
DOI: 10.1186/s12894-022-00959-z
Abstract: Background Intravesical bacillus Calmette-Guérin (BCG) fails in a considerable proportion of non-muscle invasive bladder cancer (NMIBC) patients despite treatment per recommended protocol. This real-world study aimed to understand the current patterns of treatment and disease… read more here.
Keywords: bcg unresponsive; treatment; bladder; bcg ... See more keywords
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.701
Abstract: 701 Background: RC is the recommended treatment (tx) option for pts with BCG-unresponsive HR NMIBC. However, RC is associated with significant risk of morbidity, mortality, and impact on quality of life (QoL); some patients may… read more here.
Keywords: bcg; bcg unresponsive; tar 200; bladder ... See more keywords
A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4596
Abstract: 4596 Background: Radical cystectomy (RC)is the standard treatment forBCG unresponsive high-risk (HR) NMIBC patients (pts). Pembrolizumab (Pem) was approved by the FDA based on Keynote-057 (41% complete response rate (CRR)) and offers a non-surgical option… read more here.
Keywords: bcg; bcg unresponsive; crr; sacituzumab govitecan ... See more keywords